Elsevier MDL Contributes 2,500 xPharm Compounds To PubChem; May Extend Partnership to Other DBs | GenomeWeb

In what a company official described as "something of an experiment," Elsevier MDL said last week that it will deposit around 2,500 structures from its xPharm database of pharmacological activity into NCBI's publicly available PubChem resource.

Phil McHale, vice president of marketing and corporate communications at Elsevier MDL, told BioInform that the agreement will serve as a test case to determine "whether this sort of linking is beneficial both to the users of PubChem and to our customers."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.